APR 19, 2017 7:00 PM SGT

WEBINAR: Patient Derived Micro Tumor systems: Future Trends towards improved testing systems

Sponsored by: PerkinElmer
  • Platform Leader - Centre for High Throughput Phenomics, Genome Institute of Singapore
      Dr. Giridharan Periyasamy is a Platform Leader of Centre for High Throughput Phenomics (CHiP-GIS) at the Genome institute of Singapore. His research focus is on the Cancer biology, Drug resistance, Disease modeling and signaling pathway networks of human diseases. In his core, he has potential to run high throughput functional and chemical genomics for target identification/ validation and proof of principle studies.

      His current focus is on discovery/identification of novel gene function(s) and phenotypes upon RNAi-mediated gene silencing or cDNA over expression for uncovering novel mechanisms of drug resistance. He is also intend to develop robust and comprehensive panel of 3D cell culture models patient derived primary cells for the characterization of different disease phenotypes, and investigate chemo-response to novel or known drugs. Furthermore he would like to establish array of next generation preclinical 3D tissue models for predictive toxicology screening and validation against traditional animal model systems.

      Prior to his current position, he worked as a Scientific Director of HTS/HCS Screening Core Facility at C-CAMP, NCBS, India and a Group Leader at Piramal Life Sciences Ltd in Mumbai India. Dr.Giri studied in Centre for Biotechnology at Anna University where he obtained his Ph.D. in Biotechnology, and he has more than 15 significant publications and 8 patents to his credit.


    DATE: April 20th, 2017
    TIME: 10:00AM SGT, 11:00AM KST, 12:00PM AEST, 2:00PM NZST

    With increasing breadth and depth of genomics studies across a range of cancers, it is now apparent that there exists significant inter and intra tumoural heterogeneity, with complex genotypes comprising of multiple co-existing genetic and epigenetic alterations. Current efforts at genomic characterization of individual cancers however, has several limitations: A significant proportion of patients invariably develop resistance to current targeted therapies, for which the mechanisms are not fully unraveled, and there remain a paucity of treatment options. More than 1 genomic alteration may co-exist, and the effect of co-mutations can be unpredictable from a target modulation perspective.

    In this project, we plan to propagate patient derived cell lines in order to allow functional studies that may expand therapeutic opportunities beyond genomic-based markers. Functional studies comprise both chemical and genetic tools that perturb the signaling networks in the primary cell cultures, in order to unravel complex signaling networks that interact through crosstalk and feedback loops, which modify therapeutic vulnerability. Such screens can therefore provide insights into mediators of resistance and sensitivities, yielding predictive biomarkers as well as novel drug combinations to circumvent drug resistance.

    Two crucial components include an efficient scalable system to explore therapeutic combinations and the development of representative preclinical models: Patient-derived cells in 3D culture models reflect an integration of genetic, epigenetic, and environmental influences, and may closely mimic the chemotherapeutic (or pathway specific inhibitor)-response of the actual tumor in patients. Thus we aim to exploit the relevance and scalability of patient-derived cell lines to perform HTS/HCS based screens.

    Learning Objectives:

    • Cancer heterogeneity and resistance 
    • Power of High content screening in disease biology 
    • 3D cell culture models and importance


    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    MAY 11, 2021 10:00 AM PDT
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
    DEC 02, 2020 8:00 AM PST
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    DEC 16, 2020 8:00 AM PST
    DEC 16, 2020 8:00 AM PST
    Date: December 16, 2020 Time: 8:00am (PST), 11:00am (EST) Molecular imaging of living specimens offers a means to draw upon the growing body of high-throughput molecular data to better under...
    NOV 18, 2020 8:00 AM PST
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    MAR 16, 2021 10:00 AM PDT
    MAR 16, 2021 10:00 AM PDT
    Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
    APR 19, 2017 7:00 PM SGT

    WEBINAR: Patient Derived Micro Tumor systems: Future Trends towards improved testing systems

    Sponsored by: PerkinElmer


    Cancer Research

    Cell Biology

    Molecular Biology

    Cancer Diagnostics


    Cancer Therapeutics




    Clinical Diagnostics

    Molecular Diagnostics

    Cell Culture

    Drug Discovery


    Clinical Research


    North America39%




    South America2%


    Registration Source

    Website Visitors100%

    Job Title


    Research Scientist15%


    Facility/Department Manager9%

    Medical Laboratory Technician9%



    Medical Doctor/Specialist6%

    Post Doc4%

    Lab Management4%

    Clinical Laboratory Scientist2%






    Academic Institution11%

    Research Institute6%


    Clinical Laboratory5%

    Biotech Company4%

    Ambulatory Care4%

    Pharmaceutical Company3%

    Medical Center2%

    Medical School2%


    Life Science Company1%

    Non-Profit Organization1%


    Industrial Company1%


    Show Resources
    Loading Comments...
    Show Resources
    • See more